The results, published in #AnnalsofOncology, show how cutting-edge sequencing technologies can be used to detect tumour-reactive immune cells in different tissues, particularly in blood, and how these insights could contribute to the development of personalised immune therapies.

A phase I trial of BMS-986365, a first-in-class dual-action therapy combining AR degradation + antagonism, show promise for heavily pretreated #mCRPC patients.

@myesmo.bsky.social #esmo #annalsofoncology

#Onco404 #Cancer #Kanser #Oncology #ClinicalTrials #ProstatKanseri #MedSky #OncSky #pcsm

📌 FGFR inhibitors (like pemigatinib, erdafitinib, infigratinib) have transformed care for FGFR-altered cholangiocarcinoma.

🚨 A new study analysis led to a model characterizing the biology of acquired resistance 🔍

#AnnalsOfOncology

#Onco404 #Cholangiocarcinoma #DrugResistance #Oncology #oncsky

Hidehito Horinouchi: Telisotuzumab Vedotin and Osimertinib in EGFR-Mutated NSCLC - OncoDaily Hidehito Horinouchi: Telisotuzumab Vedotin and Osimertinib in EGFR-Mutated NSCLC / Annals of Oncology, cancer, EGFR-mutated NSCLC, Hidehito Horinouchi, NSCLC,

Telisotuzumab Vedotin and Osimertinib in EGFR-Mutated NSCLC - Hidehito Horinouchi
@hhorinouchi.bsky.social

oncodaily.com/insight/hide...

#AnnalsOfOncology #Cancer #EGFRMutated #NSCLC #Health #OncoDaily #Oncology #Osimertinib #Medicine #Telisotuzumab #Vedotin

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer - OncoDaily Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer / AACR, Annals of Oncology, ASCO, biomarkers, cancer, ESMO, European Society for Medical

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #OncologistNearMe #Oncology #Medicine #Health #Cancer #ESMO #France #GustaveRoussy #AACR #AnnalsOfOncology #ASCO #Biomarkers

Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT Trial embedded phase II populatio... The FOxTROT trial has reported advantages of neoadjuvant chemotherapy (NAC) in locally advanced colon cancer (LACC). Here we present results of the embedded randomized phase II trial testing the addit...

Do anti-EGFR agents help in locally advanced colon cancer?

Check out our latest #AnnalsOfOncology paper:

www.annalsofoncology.org/article/S092...

@jenseligmann.bsky.social

Fabrice André has been elected as the President of the ESMO for the term 2025-2026 - OncoDaily Fabrice André has been elected as the President of the ESMO for the term 2025-2026 / Annals of Oncology, cancer, ESMO, Fabrice Andre, Headlines, OncoDaily,

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

oncodaily.com/insight/fabr...

#AnnalsOfOncology #Cancer #ESMO #OncoDaily #Oncology #Medicine #Health

Actions to Boost Lung Cancer Research and Innovation - OncoDaily Actions to Boost Lung Cancer Research and Innovation / Annals of Oncology, B.E. Johnson, C. Aggarwal, cancer, Cancer research, F.R. Hirsch, K. Kelly, Lung

Actions to Boost Lung Cancer Research and Innovation

oncodaily.com/insight/lung...

drgreeklungcancer.bsky.social

#AnnalsOfOncology #Medicine #Health #Oncology #OncoDaily #cancer

📖 #AnnalsOfOncology #DYK
Alongside Annals of Oncology, ESMO’s portfolio includes ESMO Open, Immuno-Oncology and Technology, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology & ESMO Rare Cancers to provide comprehensive insights across #Oncology

🔗 ow.ly/exiT50UgvZl

📖 #AnnalsOfOncology #MilestonesMonday: In 2008 Annals_ of Oncology became the official journal of the Japanese Society of Medical Oncology expanding its global influence and matching the society’s global expansion. #ESMO
🔗 ow.ly/9LCT50U8U9f

📖 Have you read "Exosome-based liquid biopsies in cancer: opportunities and challenges", one of Annals of Oncology’s top-cited papers of 2023?
#CancerResearch #AnnalsOfOncology
🔗 ow.ly/9AYe50U7MNP

📖 To mark 35 years of Annals of Oncology, putting a 2023 top-cited paper in the spotlight: "High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types."
#AnnalsOfOncology
🔗 ow.ly/pbE650U7MPt

📖 #AnnalsOfOncology #DYK In December 1990 Annals of Oncology published its first ESMO Congress abstract book, featuring 481 abstracts from 25 countries.
🔗 ow.ly/EZc450U6NfO

📖 #AnnalsOfOncology #MilestonesMonday: In 2000, David Kerr succeeded Franco Cavalli to become the second Editor-in-Chief of Annals of Oncology shaping its next decade of impactful publications.
ow.ly/NiT850U6N8i

📖 #AnnalsOfOncology #MilestonesMonday: The very first issue of Annals of Oncology was published in January 1990 with Franco Cavalli as founding Editor-in-Chief. Since then, it’s been a key resource for Oncology Research and practice worldwide.

🔗 ow.ly/wHRu50U6MWV